Blood transfusion-transmissible malaria and its cost analysis in Hawassa regional blood bank, Southern Ethiopia

Seblewongel Tsehay¹, Fatuma Hassen², Agete Tadewos Hirigo³, Zinegnaw Abiy⁴ and Kassu Desta²

Abstract

Background: Blood transfusion is an intervention used to save life particularly for those patients who survive only with receiving blood. Establishing effective diagnostic test menus concerning the screening of transfusion-transmissible infections in the blood banks play a vital role to safeguard recipients from transfusion-transmissible infections.

Objective: The aim of this study was to assess blood transfusion-transmissible malaria and its screening cost analysis in Hawassa regional blood bank, Hawassa, Sothern Ethiopia.

Methods: An institutional-based cross-sectional study was conducted from April to May 2018 among 414 voluntary blood donors. Each participant’s blood sample was screened for most transfusion-transmissible infections using antigen/antibody tests, while rapid diagnostic test and microscopy were used for malaria screening and confirmation. In addition, the cost screening of transfusion-transmissible infections was calculated using activity-based costing method.

Results: The overall seropositivity of transfusion-transmissible infections was 7.0% and the positivity rate of hepatitis B virus, syphilis, and Plasmodium falciparum was 5.6%, 1.0%, and 0.5%, respectively. The cost per test of each transfusion-transmissible infection was US$5.04 for human immunodeficiency virus, US$4.61 for hepatitis B virus, US$5.11 for hepatitis C virus, and US$4.75 for syphilis, while the cost per test of malaria rapid diagnostic test was US$4.74 and this is comparatively lower than the cost per test of other transfusion-transmissible infections except for hepatitis B virus. In addition, total cost of laboratory incurred for transfusion-transmissible infections screening is estimated to be US$213,634.5 per year, while it becomes US$265,537.5 if the malaria screening cost is added. This means 19.54% of the total cost of laboratory incurred per year or US$51,903.

Conclusion: The positivity rate of malaria parasites among voluntary blood donors was 0.5%, and it might be increased if the study was conducted in high transmission seasons. A cost of malaria screening is comparatively lower than costs of other transfusion-transmissible infections except for hepatitis B virus. Therefore, the screening of malaria parasites should be considered as one of the test menus of transfusion-transmissible infections in blood banks, especially in malaria-endemic areas.

Keywords

Cost analysis, transfusion-transmitted infections, malaria, donors, blood screening, Hawassa blood bank

Date received: 18 March 2020; accepted: 29 May 2020

Background

Malaria is a protozoan disease, and an infected female Anopheles mosquito is an intermediate host for Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale, and Plasmodium malariae species. In addition to the bite of an infected female Anopheles mosquito, malaria could also be transmitted through blood transfusion from malaria-infected donors’ blood to recipients.¹ Besides, malaria parasite was reported as a transfusion-transmissible infection (TTI) for the first time in 1911.²

Blood transfusion is an intervention that is used to save patients’ life for those who survive only with receiving

¹Hawassa University Comprehensive Specialized Hospital, College of Medicine and Health Science, Hawassa University, Hawassa, Ethiopia
²Department of Medical Laboratory Science, Addis Ababa University, Addis Ababa, Ethiopia
³School of Medical Laboratory Sciences, College of Medicine and Health Science, Faculty of Medicine, Hawassa University, Hawassa, Ethiopia
⁴College of Business and Economics, Addis Ababa University, Addis Ababa, Ethiopia

Corresponding author:
Seblewongel Tsehay, Hawassa University Comprehensive Specialized Hospital, College of Medicine and Health Science, Faculty of Medicine, Hawassa University, P.O. Box 1560, Hawassa 1560, Ethiopia.
Email: seble1325@gmail.com

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
of blood donors in Cameroon, 12.1% in Northern Ethiopia, and 0.3% in Southern Ethiopia were specifically infected with malaria parasites, Chagas disease, and human T-cell lymphocytic viruses is also highly recommended to control further spread of these infectious diseases from donors to recipients. Blood banks of most sub-Saharan countries utilize microscopic method for the diagnosis of malaria. In addition, malaria rapid diagnostic tests (RDTs) are used as an alternative and cost-effective screening method when compared to other diagnostic approaches particularly in resource-limited African settings.

World Health Organization (WHO) recommends malaria screening from blood donors who are living in malaria-endemic countries. However, few blood bank centers in sub-Saharan Africa implemented malaria screening due to a lack of evidence about the economic feasibility of screening methods. The screening of transfusion-transmissible malaria (TTM) from donors’ blood requires the application of standard methods like microscopic detection and or rapid diagnostic kits in malaria-endemic areas.

The overall 8-year prevalence of malaria in Sidama zone, Southern Ethiopia, was 21.8% with yearly declining trends of infection from 2010 to 2017: 54.6%, 42%, 28%, 22.7%, 18.7%, 12.7%, 9.0%, and 5%, respectively. About 27.5% of blood donors in Cameroon, 1% in Northern Ethiopia, and 0.3% in Southern Ethiopia were specifically infected with malaria. Concerning the diagnostic sensitivity, 168 of 187,564 blood donors were positive for malaria infection by enzyme-linked immunosorbent assay (ELISA), which means 0.089% of the total participants, while 164 of 187,564 (of the same samples) were positive by thick blood film microscopy, which means 0.087% of the total participants.

Southern Ethiopia is one of malaria-endemic regions in Ethiopia, so blood donors might be more susceptible to the risks of malaria infection; yet, there is no established practice of malaria screening and still not comprised as one of the test menus in blood bank. Therefore, this study was aimed to assess TTM and its screening cost analysis in Hawassa regional blood bank, Hawassa, Southern Ethiopia.

**Methodology**

**Study settings and study population**

This institutional-based cross-sectional study was conducted from April to May 2018 among voluntary blood donors in Hawassa regional blood bank, Southern nations, nationalities, and people’s region (SNNPR). The study was conducted in one of the malaria-endemic seasons in the study area. Hawassa regional blood bank was established in May 2013 with US$209,609.16 cost for building, and now it serves as a center for other blood banks that are found in the region. In addition, the blood bank supplies the donated blood to governmental as well as private hospitals that are found in Sidama zone, Gedio zone, Halaba zone, and other nearby sites in the region. The blood bank mainly performs the screening of major TTIs like HIV, HBV, HCV, and syphilis from donated blood before distributing to different public/private health institutions. Moreover, Southern Ethiopia is one of malaria-endemic areas in the country and donors come from such malaria-endemic locations, yet malaria screening is not practical in the blood bank as one of the test menus of TTIs.

**Sample size and sampling procedure**

Due to the absence of malaria prevalence rate among voluntary blood donors, the sample size was calculated using the assumption of 50% proportion by a single population proportion formula at a 95% confidence interval (CI)

\[
n = \frac{\left(\frac{Z_{\alpha/2}}{2}\right)^2 \times p(1-p)}{d^2} = \frac{(1.96)^2 \times 0.5(1-0.5)}{(0.05)^2} = 384
\]

where n is the required sample size, \(Z_{\alpha/2}\) (Z alpha over 2) is 1.96 at 95% CI, p is the proportion of malaria infection, q = 1 – p, and d is the marginal error (5%). In addition, a 10% non-response rate was considered and the final sample size was calculated to be 422.

All voluntary blood donors who came to the blood bank during the study period were eligible for the study using a convenient sampling technique. However, the blood donors incapable to donate due to different reasons based on the donation criteria were excluded from the study.

**Assessments and measurements**

Currently, replacement type of blood donation is not applicable in Ethiopia according to the national policy of blood bank and that is why the study included only voluntary donors who were eligible to donate blood as per blood bank criteria. The questionnaire and consent form were adopted from the national blood bank information sheet. In addition, socio-demographic status was obtained from the questionnaire of blood bank, and the result of TTIs was obtained from the laboratory logbook except for the results of malaria.

**Malaria diagnosis using RDT and microscopic examination**

Malaria screening and the result confirmation were done using RDT kits and microscopic examination for each donor, respectively. The CareStart™ Malaria HRP-2/pLDH(Pf/Pv) combo RDT kits (Access Bio, Inc., Somerset, NJ, USA) were used to screen malaria parasites. The RDT is an immunochromatographic test coated with monoclonal antibodies in two separate...
bands to distinguish malaria-specific antigens. The one is histidine-rich protein-2 (HRP-2) antigen for detecting *Plasmodium falciparum* malaria and the other is plasmodium lactate dehydrogenase (pLDH) antigen for detecting *Plasmodium vivax* malaria. About 5 μL of each donor blood sample was added using a loop supplied with the kit. The test procedure and results of malaria test kits interpretation were done as per the manufacturer’s directions. The presence of two visible bands (one in the test area and one in the control area) or three visible bands (two in the test area and one in the control area) indicates the presence of malaria parasite infection. However, only one visible line appears in the control area within 20 min if a test is negative for malaria parasite infection.

Both thick and thin smears from each donor’s blood were prepared in the same grease-free and clean microscopic glass slide and labeled properly. In addition, these thick and thin blood smears were allowed to air dry in a dustless and pest-free place. Then, thin smears were fixed with absolute methanol and stained with 10% Giemsa solution for 12–15 min using staining jars. Finally, *Plasmodium* species examination and identification were done using both thick and thin blood films by two laboratory technologists independently.

### Cost analysis procedure

All direct variables and fixed costs were computed, and the fixed costs included the costs of building, equipment, and personnel salary, while variable costs included materials and the supply cost. The cost of plant assets was calculated by deducting the depreciation cost from the original cost of the asset, and the overhead cost was assigned using an appropriate allocation rate. Besides, the straight-line depreciation method was used to compute the current value of the book value of assets for the building of useful life. It was estimated for 50 years by engineers and it requires US$209,609.16 to build it. The useful life for all types of equipment was estimated based on biomedical engineers’ information and the cost of purchasing, whereas the original cost of materials and equipment supplies was obtained from the respective voucher and based on the current study period market value (Table 1, Panel A). Moreover, the direct labor cost was the salary of laboratory technicans and technologists, while indirect labor cost was the salary of the chief executive officer (CEO), the cleaner, and the security guard. This direct labor cost was distributed for tests performed per month to get a salary per test (Table 1, Panel B).

The utility expense was computed by dividing the annual budget for 365 days of the year to get an estimated utility amount per day and distributed to the number of samples performed per day to get the utility cost per sample (Table 2, Panel A). In addition, the variable cost of each TTI includes materials and supplies which were used by each test incurred and this cost varies from one test to another. Furthermore, the variable unit cost was computed by dividing the total cost by the number of supplies or materials required per test (Table 2, Panel B).

### Operational definition

- **Screening cost per test of each TTI**: it is the sum of fixed cost per test and variable cost per test of each TTI.
- **Screening cost per test of malaria**: it is the sum of fixed cost per test and variable cost per test of malaria.
- **Activity-based costing (ABC)**: it is a costing that provides decision-making information by computing the cost of a product/test by focusing on assigning the costs contributing to specific tests and by allocating overhead costs accordingly.
- **Cost to be added for malaria screening/total malaria screening cost**: it is the total cost of laboratory minus total TTI screening cost.
- **Fixed costs**: these are costs that do not vary with the number of goods or services a company produces like building, equipment, and personnel salary costs.
- **Variable costs**: these are costs that fluctuate as the level of production or service changes like utility expense, materials, and supply costs.
- **Depreciation cost**: it is the physical deterioration of an asset over a period that spans several years.
- **Book value**: it is the current value of an asset after deducting the accumulated depreciation from the original cost of an asset.
- **Blood donation**: it refers to the process of collecting, testing, preparing, and storing blood and blood components.
- **Blood transfusion**: it is the procedure of transfer of blood or blood products from one person (donor) into another person’s bloodstream (recipient).
- **Transfusion-transmissible malaria (TTM)**: it is a malaria infection caused by the transfusion of *Plasmodium* species–infected blood to recipients.
- **Overhead costs**: these are indirect costs that cannot be traced back to a specific product as well as ongoing administrative expenses.

### Data quality assurance

RDT kits and microscopic examination quality assurance were managed according to the standard operating procedure (SOP) using both malaria-positive and -negative quality control samples. Malaria-positive and -negative patients’ blood was taken from a nearby hospital to assess the agreements between RDT kits and microscopic examination quality assurance were managed according to the standard operating procedure (SOP) using both malaria-positive and -negative quality control samples. Malaria-positive and -negative patients’ blood was taken from a nearby hospital to assess the agreements between RDT kits and microscopic examination. In addition, microscopic examination of blood films was maintained by double-blind examination using expert laboratory technologists.

### Statistical analysis

Initially, all data were visually checked and entered into an excel sheet and then exported to the Statistical Package for Social Sciences (SPSS, version 20) for statistical analysis. Data were described using descriptive statistics, and the
Results were summarized as frequencies and percentages. In addition, the cost analysis was computed using ABC costing method.\textsuperscript{16}

### Results

**Socio-demographic characteristics of the study participants**

Totally 422 blood donors approached and of them, 414 (98.1\%) were included in the study; 228 (55.1\%) donors were females, 87.4\% were students, and 51.9\% of the donors aged 19–24 years (Table 3).

**TTIs and the costs of laboratory tests**

The blood bank annually performs 10,950 tests per type of infection (HBV, HIV, HCV, and syphilis) other than malaria, which means around 43,800 tests per year. The overall seropositivity of TTIs was 29 (7.0\%). The positivity rate of HBV, syphilis, and malaria (*Plasmodium falciparum*) was 23 (5.6\%), 4(1.0\%), and 2(0.5\%), respectively. However, the donors were seronegative for HIV, HCV, and other species of malaria infections. Both RDT kits and blood smears showed the same results for malaria parasite infection.

The current cost of the building (book value) was estimated to be US$192,840.43. Therefore, the building cost for each sample was calculated through dividing the book value by the total number of samples per year and it was found to be US$17.6. Subsequently, the building cost was distributed to all tests including malaria and it was US$3.52 per test. Other fixed costs of the equipments were calculated based on the utilized tests and most TTI screening shared equipments equally, and this cost was distributed for each TTI (Table 4).

The indirect cost, such as the salary of CEO and the supportive staff, was distributed for all TTIs including malaria and it was US$0.15 per test. The labor cost for each TTI per test was calculated to be US$ 0.44, while the estimated labor cost per test of malaria screening was calculated to be US$0.16. In addition, the utility expense for each TTI per test except malaria was US$0.0125 (0.05/4), while the variable cost per test was found to be US$0.73 for HIV, US$0.8 for HCV, US$0.3 for HBV, US$0.44 for syphilis, and US$0.86 for malaria. Moreover, the variable cost of

| Table 1. Cost plant asset and labor costs of Hawassa regional blood bank. |
|--------------------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| **Panel A: Accumulated depreciation assets of Hawassa regional blood bank from 2013 to 2018** |
| **Asset** | **Life span in years** | **Cost in 2014** | **Accumulated depreciation year 2014-2017** | **Book value in 2017** |
| Building | 50 | 209,609.16 | 4192.18 | 8384.36 | 12,576.54 | 16,768.72 | 192,840.43 |
| ELISA reader | 7 | 1648.15 | 235.45 | 470.9 | 706.35 | 941.8 | 706.35 |
| ELISA washer | 7 | 1648.15 | 235.45 | 470.9 | 706.35 | 941.8 | 706.35 |
| Autoclave | 12 | 1055.55 | 87.96 | 175.3 | 263.88 | 351.85 | 703.7 |
| Incubator | 10 | 1037.04 | 103.70 | 207.4 | 311.1 | 414.8 | 622.24 |
| Shaker | 10 | 814.80 | 81.48 | 162.96 | 244.44 | 325.92 | 488.88 |
| Micropipette | 10 | 55.55 | 5.56 | 11.12 | 16.68 | 22.22 | 33.33 |
| Water bath | 10 | 1055.55 | 105.56 | 211.2 | 316.68 | 422.4 | 633.15 |
| Centrifuge | 12 | 740.74 | 74.07 | 148.14 | 222.21 | 296.28 | 444.46 |
| Refrigerator | 12 | 925.93 | 77.16 | 154.32 | 231.48 | 308.64 | 617.29 |

| **Panel B: Labor cost of Hawassa regional blood bank in 2018** |
| **Variable** | **Salary per month (30 days)** | **No. of staffs** | **Salary per day** | **No. of samples per day** | **Salary per sample** |
| Salary of CEO | 371.26 | 1 | 12.37 | 30 | 0.41 |
| Salary of lab technologist | 298.4 | 3 | 29.84 | 30 | 0.99 |
| Salary of lab technician | 144.78 | 1 | 4.82 | 30 | 0.16 |
| Salary of cleaner | 42.67 | 3 | 4.27 | 30 | 0.14 |
| Salary of security | 42.67 | 4 | 5.69 | 30 | 0.19 |

ELISA: enzyme-linked immunosorbent assay; CEO: chief executive officer.

Cost assessment was done in US$; US$1 is equal to 27 Ethiopian Birr during the study period. “A” is the salary scale paid for 30 days (a 1-month salary in Ethiopia situation); salary per day = salary scale (A) × number of staffs (B) divided by 30 days for each row.
materials used for all TTIs per test including malaria was US$0.05 (0.25/5). Therefore, the cost per test was US$5.04 for HIV, US$4.61 for HBV, US$5.11 for HCV, and US$4.75 for syphilis, while the cost per test of malaria was US$4.74, which is relatively lower than the cost per test of other TTIs except for HBV (Table 5).

Cost to be added for malaria screening

The total cost of laboratory incurred for the screening of TTI except for malaria was estimated to be US$21,3634.5 per year, while the cost becomes US$265,537.5 if malaria screening cost is included. This reflects the addition of US$51,903 in the total cost of laboratory incurred per year or 19.54% of the total cost (Table 6).

Discussion

Blood transfusion can be a life-saving technique, but it has risks of containing infectious and noninfectious agents. The infectious agents can be transmitted through transfusion easily and that is why all the donated blood requires the screening of major TTIs like HIV, HBV, HCV, and syphilis in the blood banks. In addition, based on the epidemiological evidence and endemic nature of the infection, the donated blood should also be screened for malaria particularly in endemic areas to prevent its transmission through transfusion.3,4 However, the provision of adequately safe blood transfusion is a big challenge in developing countries including Ethiopia. That is why the WHO urges voluntary donation rather than the replacement one for minimizing the risks of TTIs.4

The current study indicated that the overall seropositivity of TTIs among voluntary blood donors was 7.0%. This is in line with the reports of previous studies that were conducted in different regions of Ethiopia: 7.0% in Yirgalem,17 7.06% in Dire Dawa,18 6.6% in Harari,19 and 6% in Bahir Dar.20 On the contrary, the rate was lower than the reports of several studies conducted in Ethiopia and Africa settings like 12.4% in Eastern Ethiopia,21 11.5% in Jigjiga,9 12.6% in South Gondar,22 10.1% in Zambia,23 15.9% in Tanzania,24 18.9% in Ghana,25 26.2% in Cameroon,26 and 19.3% in Nigeria.27 The findings of this study were also higher than the rates reported from Eritrea28 and Namibia29 which were

---

Table 2. The utility expense and variable costs of Hawassa regional blood bank, Hawassa, 2018.

| Panel A: The utility expense of Hawassa regional blood bank |
| Utility | Annual expense | Average expense | Expense per day | Test done per day | Utility per sample |
|---------|----------------|-----------------|-----------------|------------------|-------------------|
| Electricity | 703.70 | 58.64 | 1.96 | 30 | 0.016 |
| Water | 555.56 | 46.30 | 1.54 | 30 | 0.013 |
| Telephone | 954.00 | 79.50 | 2.65 | 30 | 0.022 |

| Panel B: The variable cost of Hawassa regional blood bank |
| Materials and supplies | Quantity | Total cost | Quantity per test | Unit cost |
|------------------------|----------|------------|------------------|-----------|
| RDT kit | 25 | 21.60 | 1 | 0.86 |
| HIV ELISA kit | 96 | 70.00 | 1 | 0.73 |
| HCV ELISA kit | 96 | 77.00 | 1 | 0.80 |
| HBV ELISA kit | 96 | 28.80 | 1 | 0.30 |
| Syphilis ELISA kit | 96 | 42.00 | 1 | 0.44 |
| EDTA tube | 50 | 8.96 | 1 | 0.18 |
| Micropipette tips | 500 | 35.00 | 1 | 0.07 |

RDT: rapid diagnostic test; HIV: human immunodeficiency virus; ELISA: enzyme-linked immunosorbent assay; HCV: hepatitis C virus; HBV: hepatitis B virus; EDTA: ethylenediaminetetraacetic acid.

Cost assessment was done in US$; US$1 = 27 Ethiopian Birr during the study period. EDTA tube + micropipette tips unit cost was divided to 5 TTIs: 0.25/5 = 0.05, and the variable cost of the materials used for each TTI including malaria became US$0.05.

Table 3. Socio-demographic characteristics of blood donors who donated blood in Hawassa regional blood bank, Hawassa, Ethiopia, April–May 2018.

| Variable | Frequency (N = 414) | % |
|----------|---------------------|---|
| Age (years) | | |
| 18 | 157 | 37.9 |
| 19–24 | 215 | 51.9 |
| >25 | 42 | 10.1 |
| Sex | | |
| Male | 186 | 44.9 |
| Female | 228 | 55.1 |
| Address | | |
| Hawassa | 255 | 61.6 |
| Dilla | 47 | 22.2 |
| Halaba | 92 | 11.4 |
| Yirgalem | 20 | 4.8 |
| Occupation | | |
| Student | 362 | 87.4 |
| Employee | 52 | 12.6 |

The total cost of laboratory incurred for the screening of TTI except for malaria was estimated to be US$21,3634.5 per year, while the cost becomes US$265,537.5 if malaria screening cost is included. This reflects the addition of US$51,903 in the total cost of laboratory incurred per year or 19.54% of the total cost (Table 6).
Table 4. The cost per test of fixed assets in Hawassa regional blood bank, Hawassa, 2018.

| Assets       | Book value per year | No. of days per year | No. of samples per day | Cost per sample | No. of tests share it | Cost per test |
|--------------|---------------------|----------------------|------------------------|-----------------|-----------------------|---------------|
| Building     | 192,840.43          | 365                  | 30                     | 17.6            | 5                     | 3.52          |
| ELISA reader | 706.35              | 365                  | 30                     | 0.064           | 4                     | 0.016         |
| ELISA washer | 706.35              | 365                  | 30                     | 0.064           | 4                     | 0.016         |
| Autoclave    | 703.7               | 365                  | 30                     | 0.064           | 4                     | 0.016         |
| Incubator    | 622.24              | 365                  | 30                     | 0.06            | 4                     | 0.014         |
| Shaker       | 488.88              | 365                  | 30                     | 0.04            | 4                     | 0.010         |
| Refrigerator | 1604.94             | 365                  | 30                     | 0.14            | 4                     | 0.040         |
| Micropipette | 33.33               | 365                  | 30                     | 0.004           | 4                     | 0.002         |

ELISA: enzyme-linked immunosorbent assay.
Cost assessment was done in US$; US$1 is equal to 27 Ethiopian Birr during the study period.

Table 5. Total cost per test of each TTI in Hawassa regional blood bank, Hawassa, Ethiopia, 2018.

| Test type | Building cost/test | Equipment cost/test | Indirect cost/test | Labor cost/test | Utility expense/test | Material cost/test | Variable cost/test | Total cost/test |
|-----------|--------------------|---------------------|-------------------|-----------------|---------------------|-------------------|-------------------|-----------------|
| HIV       | 3.52               | 0.14                | 0.15              | 0.44            | 0.0125              | 0.05              | 0.73              | 5.04           |
| HCV       | 3.52               | 0.14                | 0.15              | 0.44            | 0.0125              | 0.05              | 0.80              | 5.11           |
| HBV       | 3.52               | 0.14                | 0.15              | 0.44            | 0.0125              | 0.05              | 0.30              | 4.61           |
| Syphilis  | 3.52               | 0.14                | 0.15              | 0.44            | 0.0125              | 0.05              | 0.44              | 4.75           |
| Malaria   | 3.52               |                     | 0.44              | 0.44            | 0.0125              | 0.05              | 0.86              | 4.74           |

TTIs: transfusion-transmissible infections; HIV: human immunodeficiency virus; HCV: hepatitis C virus; HBV: hepatitis B virus; RDT: rapid diagnostic test; EDTA: ethylenediaminetetraacetic acid.
Cost assessment was done in US$; US$1 is equal to 27 Ethiopian Birr during the study period. Utility cost: malaria RDT diagnosis does not require utility and equipment, so the expense was distributed to the rest of four TTIs. Material cost is the cost of EDTA test tube and micropipette, which was 0.25/5 = 0.05. The number of donors was assessed in the blood bank for averaging the number of daily donation and the average was 30 per day, 10,950 per year, 10,950 tests required for each TTI, and 43,800 tests per year for all TTIs except for malaria. A cost pertest was calculated by the summation of variable cost and fixed cost. Building (book value) was estimated to be US$192,840.43; the allocation of this cost per test = 192,840.43 / (10,950 × 5 types of TTIs) = 3.52 for each including malaria. Equipment cost was estimated to be US$5943.4; the allocation of this cost per test = 5943.4 / (10,950 × 4 types of TTIs) = 0.14 for each because malaria RDT does not require equipments. In addition, similar manner was applied to calculate other types of cost per test.

Table 6. Costs of each TTI and a cost to be added for malaria screening in Hawassa regional blood bank, Hawassa, 2018.

| Type of tests | Fixed cost per test | Fixed cost/year | Variable cost per test | Variable cost/year | Total cost/year |
|---------------|---------------------|-----------------|------------------------|--------------------|-----------------|
| HIV           | 4.31                | 47,194.5        | 0.73                   | 7993.5             | 55,188          |
| HCV           | 4.31                | 47,194.5        | 0.8                    | 8760               | 55,954.5        |
| HBV           | 4.31                | 47,194.5        | 0.3                    | 3285               | 50,479.5        |
| Syphilis      | 4.31                | 47,194.5        | 0.44                   | 4818               | 52,231.5        |
| Malaria       | 3.88                | 42,486          | 0.86                   | 9417               | 51,903          |

Costs

| Costs                      | Total fixed cost/year | Total variable cost | Total cost/year |
|----------------------------|-----------------------|---------------------|-----------------|
| Estimated cost of the lab per year (without including malaria screening cost) | 188,778 | 24,856.5 | 213,634.5 |
| Total cost of the lab per year (with including malaria the screening cost) | 231,264 | 34,273.5 | 265,537.5 |
| A cost to be added for malaria screening per year | 42,486 | 9417 | 51,903 |

TTIs: transfusion-transmissible infections; HIV: human immunodeficiency virus; HCV: hepatitis C virus; HBV: hepatitis B virus.
Total cost of the lab = total fixed cost + total variable cost.
Total fixed cost = book value of assets + labor cost.
Variable cost = utility expense + material and supplies cost.
Variable cost per year for each type of test = (variable cost per test × 30 tests/day × 365 days/year).
Fixed cost per year for each type of test = (fixed cost per test × 30 tests/day × 365 days/year).
3.6% and 1.4%, respectively. The variations could be attributed to differences in the studies’ sample size, geographical locations for the disease distribution, donation type (replacement or voluntary), the study design, and behavioral condition of the population across locations. In addition, the sensitivity and specificity levels of the diagnostic kits might have a contribution to the variations of seropositivity rates between the studies.

Studies conducted in different regions of Ethiopia revealed different seropositivity rate of HIV and HCV: 1.24% and 0.96% in Dire Dawa,18 0.5% and 0.6% in Bahir Dar,20 2.6% and 4.2% in South Gondar,22 and 1.4% and 1% in Eastern Ethiopia.21 On the contrary, we found that none of the blood donors were positive for HIV and HCV. Both voluntary and replacement type of donations were involved in the depicted studies, while only voluntary blood donors were included in the current study and this might be a reason for the rate inconsistency between the studies.

The current study indicated a 5.6% seropositivity rate of HBV infection. Similarly, the study conducted by Negash et al.23 indicated that 5.8% of the blood donors were infected with HBV in 2019. However, the finding was lower than the rate reported from different African countries: 10.5% in Ghana,30 10.6% in Mozambique,31 10.9% in Nigeria,32 and 8.8% in Tanzania.24 The tradition of society, the geographical distribution of disease-causing agents, and individuals’ sexual behaviors might be the plausible factors for the variations.

We found 1.0% seropositivity rate of syphilis and this was almost comparable with the rate reported by Shiferaw et al.20 from Bahir Dar, Awan et al.33 from Islamabad, and Siraj et al.28 from Eritrea, which were 1.2%, 0.75%, and 0.6%, respectively.

The rate of malaria in this study was 0.5%. This finding is comparable with the study reported from Bangladesh,34 which was 0.76%. However, the rate was higher than the two studies conducted in Pakistan, which were 0.02%33 and 0.07%35. The variation might be attributed to differences in malaria diagnostic methods between the studies, seasonal situations for mosquito breeding, and malaria outbreaks. Our study finding indicates around 50 individuals per 10,000 blood donors will be infected with malaria parasites if the blood transfusion was done without malaria screening. In other expression, about 50 individuals per 10,000 recipients have a probability to be infected with malaria parasites through unscreened blood transfusion. This may increase the risks of comorbidity with malaria infection. In addition, the outcome of such transfusion might lead to bad consequences such as fatality in pediatric and gynecology cases which may occur unknowingly due to the high susceptibility rate of infections.

This study indicates the same result for malaria infections using both RDT kits and microscopic examination and the finding is comparable with the study reported by Torresa et al.36 The current study indicates the cost per test of malaria RDT is about US$4.74, which is relatively lower than the cost per test for other TTIs except for HBV. Most studies suggested that RDT is cost-effective when compared to microscopic examination and expected to be cost-effective when compared to presumptive diagnosis.37–39 In addition, the study from Afghanistan indicated the cost-effectiveness of RDT kit utilization in resource-limited areas.35 Moreover, malaria RDTs are a potential alternative when compared to both clinical assessment and microscopic diagnosis, and it is easier to diagnose, needs limited training, and has high accuracy.37,40–43 In support, poor performance of routine microscopy has been widely known, even in developed countries,44 and high investment assets of microscopy make it more costly than RDT in areas where malaria infection is very low.45

The current study indicates about US$51,903 of an estimated cost or 19.54% of the total cost of the laboratory incurred per year to be added if malaria screening cost is considered. In addition, this cost is somehow lower than the costs of other TTIs except for HBV; and malaria screening from blood donors is vital if it could be comprised as one of the test menus in a blood bank. However, the lower cost per test for malaria was reported from Kenya and the computed cost per test for malaria screening was US$0.03.46 The cost variations might be attributed to materials accessing opportunities, inside the production of diagnostic supplies, and the period of the studies conducted.

Limitations of the study

First, we only analyzed the cost of RDT kits that was one of malaria screening methods and the costs of alternative malaria screening methods like microscopic diagnosis, ELISA, and polymerizing chain reaction (PCR) were not assessed. Second, this study used a convenient sampling technique, which is a non-probability sampling technique for participants’ inclusion and it might be exposed to the effect of outliers. Third, this study was conducted in a moderate malaria transmission season, but the increased rate might be observed if the study was conducted during a high transmission season, which means from October to January. Regardless of the described limitations, this study eventually adds helpful information concerning the rate of TTM in the limited data situation of African countries including Ethiopia.

Conclusion

The cost to be added for malaria screening is 19.54% of the laboratory incurred per year, and the cost per test for malaria RDT is relatively lower than the total screening cost per test and the cost per test of other TTIs except for HBV. In addition, a 0.5% of malaria positivity rate was observed in one of the malaria transmission seasons in the study site. However, this rate might be increased if the study was conducted during a high transmission season, which means from October to
January. Still, malaria diagnosis is not applicable in the blood bank as one of the TTI test menus, and this might expose individuals for the receipt of malaria parasites through malaria parasite–infected blood transfusion. Therefore, the diagnostic efforts should be done to avoid TTM through dedicated malaria screening among blood donors mainly in malaria-endemic areas and its screening should be incorporated in the blood bank protocol for the benefit of blood recipients and the donors as well. Moreover, the cost analysis that is undertaken in this article suggests the utilization of RDT kits in terms of cost-effectiveness and its suitability to screen malaria infection.

Acknowledgements

The authors want to acknowledge the Addis Ababa University College of Health Sciences, Department of Medical Laboratory Sciences for providing the financial support. In addition, the authors’ appreciation goes to Mrs Muluberhan Ali (Hawassa University Comprehensive Specialized Hospital laboratory coordinator), Mrs Buzayehu Belachew (the CEO of Hawassa regional blood bank), and all lab staffs of Hawassa University Comprehensive Specialized Hospital and Hawassa regional blood bank for their support during data collection. Furthermore, they want to acknowledge the blood donors for their voluntary participation in the study.

Author contributions

All listed authors participated in this project. K.D. conceptualized the idea of this work; S.T. contributed to study design, data collection, and data analysis; K.D., F.H., and Z.A. were advisors throughout the project; and A.T.H. contributed to manuscript preparation, compulsory analysis, and appraisal. All authors read and approved the final version of the manuscript.

Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The study was financially supported by Addis Ababa University, Department of Medical Laboratory Science.

Availability of data and materials design

The authors declare that all important data are fully described in the manuscript.

Ethical approval

Ethical approval was obtained from departmental research and ethical review committee of Addis Ababa University, Department of Medical Laboratory Science (AAU/March-2018). Following this, an official support letter was submitted to Hawassa regional blood bank.

Informed consent

Written informed consent was obtained from all participants before the study. All the study participants were well informed about the procedure of the study, and confidentiality of the data was well kept.

ORCID iD

Seblewongel Tsehay https://orcid.org/0000-0001-5034-618X

References

1. Seed R, Kitchen A and Davis T. The current status and potential role of laboratory testing to prevent transfusion-transmitted malaria. Transfus Med Rev 2005; 19: 229–240.
2. Kitchen D and Chiiodini L. Malaria and blood transfusion. Vox Sang 2006; 90: 77–84.
3. World Health Organization (WHO). National standards for blood transfusion service. Thimphu, Bhutan: Ministry of Health, 2013.
4. World Health Organization (WHO). Screening donated blood for transfusion- transmissible infections. Geneva: WHO, 2010.
5. Alex K, Owusu O, Christopher P, et al. Transmitted malaria in countries where malaria is endemic: a review of the literature from Sub-Saharan Africa. Clin Infect Dis 2010; 51: 1192–1198.
6. Moiz B. Prevention of transfusion transmitted malaria in an endemic area: a challenge for blood banks. Infect Dis J Pak 2004; 1: 96–98.
7. World Health Organization (WHO). Guidelines on assessing donor suitability for blood donation, 2012, https://www.who.int/bloodsafety/publications/BDSélection_WHO_GuideAssessingDonorSuitability4BloodDonation.pdf
8. Allain P. Malaria and transfusion: a neglected subject coming back to the forefront. Clin Infect Dis 2010; 51: 1199–1200.
9. Mohammed Y and Bekele A. Seroprevalence of transfusion-transmitted infection among blood donors at Jijiga blood bank, Eastern Ethiopia. BMC Res Notes 2016; 9: 129.
10. Dobartiya G, Raja A, Unagar A, et al. Prevalence and trends of transfusion-transmitted infections among blood donors of blood bank attached to government hospital of South Gujarat, India. Int J Res Med Sci Depar 2016; 4: 4123–4127.
11. Dabaro D, Birhanu Z and Yewhalaw D. Analysis of trends of malaria from 2010 to 2017 in Boricha District, Southern Ethiopia. Malar J 2020; 19(1): 88.
12. Mogtomo K, Foko K, Okoubalimba A, et al. High risk of transfusion-transmitted malaria (TTM) from student blood donors living in the town of Douala, Cameroon. J Clin Infect Dis Prac 2016; 1: 108.
13. Gelaw B and Mengistu Y. The prevalence of HBV, HCV and malaria parasites among blood donors in Amhara and Tigray regional states. Ethiop J Health Dev 2008; 22: 3–7.
14. Bonja F, Hussein M, Alemu J, et al. The prevalence of transfusion transmitted infections: a focus on hepatitis B virus among blood donors at Hawassa blood bank center, Southern Ethiopia. Int J Blood Trans Immun 2017; 7: 7–14.
15. Lakshmi S and Anuradha B. Prevalence of malaria in blood donors and risk of transfusion transmissible malaria. Int J Curr Microbiol App Sci 2015; 4: 352–357.
16. Rajabi A and Dabiri A. Applying activity based costing (ABC) method to calculate cost price in hospital and remedy services. Iran J Public Health 2012; 41(4): 100–107.
17. Birhaneselassie M. Prevalence of transfusion-transmissible infections in donors to an Ethiopian blood bank between 2009
and 2013 and donation factors that would improve the safety of the blood supply in underdeveloped countries. Lab Med 2016; 47: 134–139.

18. Ataro Z, Urgessa F and Wasihun T. Prevalence and trends of major transfusion transmissible infections among blood donors in Dire Dawa blood bank, Eastern Ethiopia: retrospective study. Ethiop J Health Sci 2018; 28(6): 701–710.

19. Teklemariam Z, Mitiku H and Weldegebreal F. Seroprevalence and trends of transfusion transmitted infections at Harar blood bank in Harari regional state, Eastern Ethiopia: eight years retrospective study. BMC Hematol 2018; 18(1): 24.

20. Shiferaw E, Tadillo W, Melkie I, et al. Seroprevalence and trends of transfusion-transmissible infections among blood donors at Bahir Dar district blood bank, northwest Ethiopia: a four-year retrospective study. PLoS ONE 2019; 14(4): e0214755.

21. Heyredin I, Mengistie B and Weldegebreal F. Seroprevalence of transfusion-transmittable infections and associated factors among blood donors in Eastern Ethiopia: an Institutional-based cross-sectional study. SAGE Open Med. Epub ahead of print 25 February 2019. DOI: 10.1177/205031219834468.

22. Negash M, Ayalew M, Geregemew D, et al. Seroprevalence and associated risk factors for HIV, Hepatitis B and C among blood Donors in South Gondar District blood bank, Northwest Ethiopia. BMC Infect Dis 2019; 19(1): 430.

23. Chama D, Ahmed Y, Baboo K, et al. Transfusion transmissible infections among voluntary blood donors at the University Teaching Hospital, Lusaka, Zambia. Med J Zambia 2015; 42: 90–95.

24. Matee MI, Magesa PM and Lyamuya EF. Seroprevalence of human immunodeficiency virus, hepatitis B and C viruses and syphilis infections among blood donors at the Muhimbili National Hospital in Dar es Salaam, Tanzania. BMC Public Health 2006; 6(1): 21.

25. Walana W, Ahiaba S, Hokey P, et al. Sero-prevalence of HIV, HBV and HCV among blood donors in the Kintampo Municipal Hospital, Ghana. Br Microbiol Res J 2014; 4(12): 1491–1499.

26. Noubiap JJ, Joko WYA, Nansseu JRN, et al. Sero-epidemiology of human immunodeficiency virus, hepatitis B and C viruses, and syphilis infections among first-time blood donors in Edéa, Cameroon. Int J Infect Dis 2013; 17(10): 832–837.

27. Nwankwo E, Mamodu I, Umar I, et al. Seroprevalence of major blood-borne infections among blood donors in Kano, Nigeria. Turk J Med Sci 2012; 42(2): 337–341.

28. Siraj N, Achila OO, Issac J, et al. Seroprevalence of transfusion-transmissible infections among blood donors at National Blood Transfusion Service, Eritrea: a seven-year retrospective study. BMC Infect Dis 2018; 18(1): 264.

29. Mavnyengwa RT, Mukesi M, Chipare I, et al. Prevalence of human immunodeficiency virus, syphilis, hepatitis B and C in blood donations in Namibia. BMC Public Health 2014; 14(1): 424.

30. Nkrumah B, Owusu M and Averu P. Hepatitis B and C viral infections among blood donors. A retrospective study from a rural community of Ghana. BMC Res Note 2011; 4(1): 529.

31. Stoks J, Gillet P, De Weggheleire A, et al. Seroprevalence of transfusion-transmissible infections and evaluation of the pre-donation screening performance at the Provincial Hospital of Tete, Mozambique. BMC Infect Dis 2011; 11(1): 141.

32. Ajugwo A, Erhabor T, Elebo D, et al. Prevalence of transfusion transmissible infections in a Nigerian tertiary hospital. J Transmis Dis Immun 2017; 12(1): 32–34.

33. Awan SA, Junaid A and Sheikh S. Transfusion transmissible infections: maximizing donor surveillance. Cureus 2018; 10(12): e3787.

34. Hoque M, Islam M, Begum H, et al. Prevalence of malaria parasites among blood donors in selected hospitals of Dhaka city. J Dhaka Med Coll 2008; 17: 94–97.

35. Arshad A, Borhany M, Anwar N, et al. Prevalence of transfusion transmissible infections in blood donors of Pakistan. BMC Hematol 2016; 16: 27.

36. Torresa L, Morescob N, Salesa R, et al. Transfusion-transmitted malaria in endemic zone: epidemiological profile of blood donors at the Fundação HEMOAM and use of rapid diagnostic tests for malaria screening in Manaus. Rev Bras Hematol Hemoter 2014; 36: 269–227.

37. Hansen K, Grieve E, Mikhail A, et al. Cost-effectiveness of malaria diagnosis using rapid diagnostic tests compared to microscopy or clinical symptoms alone in Afghanistan. Malar J 2015; 14(1): 217.

38. Hansen K, Ndyomugenyi R, Magnussen P, et al. Cost-effectiveness analysis of malaria rapid diagnostic tests for appropriate treatment of malaria at the community level in Uganda. Health Policy Plan 2017; 32(5): 676–689.

39. Tawiah T, Hansen KS, Baiden F, et al. Cost-effectiveness analysis of test-based versus presumptive treatment of uncomplicated malaria in children under five years in an area of high transmission in Central Ghana. PLoS ONE 2016; 11: e0164055.

40. Abba K, Deeks JJ, Olliaro P, et al. Rapid diagnostic tests for diagnosing uncomplicated P. falciparum malaria in endemic countries. Cochrane Database Syst Rev 2011; 7: CD008122.

41. Oliveira MRF, Giozza SP, Peixoto HM, et al. Cost-effectiveness of diagnostic for malaria in extra-Amazon region, Brazil. Malar J 2012; 11: 390.

42. Uzochukwu B, Obikeze E, Onwujeke W, et al. Cost-effectiveness analysis of rapid diagnostic test, microscopy and syndromic approach in the diagnosis of malaria in Nigeria: implications for scaling-up deployment of ACT. Malar J 2009; 8(1): 265.

43. Hassanpour G, Mohebali M, Raesi A, et al. Detection of malaria infection in blood transfusion: a comparative study among real-time PCR, rapid diagnostic test and microscopy. Parasitol Res 2011; 108: 1519–1523.

44. Wongsrichanalai C, Barcus MJ, Muth S, et al. A review of malaria diagnostic tools: microscopy and rapid diagnostic test (RDT). Am J Trop Med Hyg 2007; 77: 119–127.

45. Bell D, Wongsrichanalai C and Barnwell J. Ensuring quality and access for malaria diagnosis: how can it be achieved? Nat Rev Microbiol 2006; 4(9): 682–695.